Share all of my holdings? Nah, it wouldn't help, and it

New Post Public Reply Private Reply Replies (0) Message Board
KolbeB Cycl2R #46956
692
Share all of my holdings? Nah, it wouldn't help, and it wouldn't be germane to this board, so it would be deleted anyway. I will say this: CYDY meets my most important requirements before buying a piece of a company...

1. A growing market in which to sell. Not only is the CYDY market uniquely expansive in the healthcare world (many indications re: Ohm20's list), but it is growing. People are getting sicker and sicker, maybe from GMO food, shots that have bad stuff in them (re: the "v" word), environmental exposure to toxins, unhealthy diets, etc etc. Many of the diseases from which we suffer are related to our immune system.

2. Innovative product(s) / little competition. There is really nothing currently out there just like Pro 140 / leronlimab. One day there will be, or some other approach / therapeutic will be introduced into the market, but for now we have a long, long runway. I don't believe vaccines will be the answer (see the flu shot)..

3. Passionate, capable, experienced, committed, fully invested management. NP and team are all in right now. Their financial future is seriously invested. In spite of the criticisms of management personnel, I believe we are still on track. I am watching this, too, although the product is so good, I am not yet concerned.

4. Market cap. Small to mid-caps can grow faster than most large caps (although LC's are important to own for stability IMO). CYDY is a perfect example of small (well, micro really) cap potential. A $10,000 investment in December would have grown to over $160,000 (1,500% gain). Granted, that's a great penny stock ($.30/sh in Dec). But given the prospects of a stock that may go to $50 in 3 years or less, that would yield a 900% gain from today's level. No FAANG stock is going to grow like that.

5. Bonus: it does something great for humanity. This is the real reason so many have asked heaven to help. It has such awesome potential here.

Smells like a winner to me!!! We will see very soon....
1

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Actinium Pharma Unveils Plans at Key Investor Conference

Updated Category News Views 2

Actinium Pharmaceuticals Steps into the Spotlight Alright, folks, here we have Actinium Pharmaceuticals, Inc. gearing up to make some noise at the H.C. Wainwright 28th Annual Global Investment Conference. This isn't just any roadshow—it's a chance to showcase the kind of pioneering work they're doing in targeted radiotherapies. With Sandesh Seth, the Chairman, taking...

Continue Reading
Dr. Rashedi Reveals Laughing Gas Safety for Kids

Updated Category News Views 0

Why Laughing Gas is a Game-Changer in Pediatric Dentistry You ever seen a kid freeze up like a deer in headlights at the dentist's office? I'm telling you, it's not just the sweet tooth nightmare but often the fear of that cold, intimidating chair. But let's talk about a game-changer: laughing gas or, known in the trade as nitrous oxide. Keeping Anxiety at Bay: The Role...

Continue Reading
Signant and Lothar Forge Future in Clinical Trials

Updated Category News Views 1

Breathing New Life into Clinical Trials Alright, folks, listen up. We've got a fresh collaboration cooking that could shake things up in the clinical trial sector. Signant Health, a heavyweight in clinical trial solutions, has teamed up with Lothar Medical, and they’ve hitched their wagons to launch something rather intriguing: the ALDS PRO pulmonary function tech. Let...

Continue Reading
2026 AI Talent Study Reveals Growth and Gaps

Updated Category News Views 2

Pushing Forward Yet Stumbling on the Details We've got a fresh scoop from the AI Leaders Council: They just rolled out their 2026 Corporate AI Talent Study. What's the big fuss? Well, they're tracking how companies are cozying up to artificial intelligence. Let's just say it's a mixed bag this time around. While almost everyone jumped on the AI bandwagon, only a scant 3%...

Continue Reading
Virterion Surges Ahead in VPS Racing With Reliable Hosting

Updated Category News Views 1

Why Virterion Stands Out in 2026 VPS Landscape For anyone knee-deep in the hosting game, you know the market's got more players than a late-night poker round. Virterion, though—that's a name carving out a noticeable niche, and for solid reasons. In 2026, the backdrop's not just speed, it’s about matching technology and support with what ambitious developers need. VPS...

Continue Reading
Patented Foodservice Firm's $1.6M Sale: High ROI Potential

Updated Category News Views 0

Cooking Up High Margins and Rapid Growth You don’t stumble on opportunities like this every day. A foodservice company out there is posting some mouth-watering numbers, and it’s shaking up the M&A scene. This one’s got patents holding up its brand like a culinary force field, and it’s now on the auction block for a cool $1.6 million. And the numbers? Well, they...

Continue Reading
XCOTTON Shines at IFA 2026: The New Horizon of Commerce

Updated Category News Views 1

Shifting Gears at the Checkout Counter Let's face it, we've all been there: you click, you pay, and then you wait. But what happens next is where brands often drop the ball. Sure, e-commerce has been all about getting us to trust the 'buy' button. That's where folks like XCOTTON are stepping up to the plate, giving us something else to consider. They were loud and clear...

Continue Reading
Dreame Unveils Vast AI Product Range at IFA 2026

Updated Category News Views 0

Overnight Sensation or Future Staple? I wonder if Dreame's top brass woke up sweating or smiling after their big reveal at IFA 2026. A buffet of over 100 products across 16 categories is no small feat, especially when you're banking on technologies developed over nine years. But let's cut through the noise—does this showcase promise innovation or just smoke and mirrors?...

Continue Reading
Inturai Ventures Closes Final Tranche with a Twist

Updated Category News Views 4

Wrapping Up a Wild Ride in the Investment Arena Markets are a fickle friend, and today we've got Inturai Ventures calling it a day on their latest cash grab. They've locked the final tranche of their private placement, pulling in an aggregate $963,713.70. Feels like they're counting pennies in this venture, but every cent counts when your aim is to shake up industries...

Continue Reading
AVEX Faces Lawsuit Over IPO Missteps

Updated Category News Views 3

Legal Storm Brewing with AEVEX's IPO Disclosures Whatever happened to straightforward honesty in business? AEVEX Corp. (NYSE: AVEX) might have forgotten that chapter judging by fresh allegations in their midst. Investors who bought AVEX Class A common stock between April 17 and June 4, 2026, have been hit with a curveball: a looming class action lawsuit for securities...

Continue Reading
ing Brands Faces Legal Probe; Fiduciary Duties Questioned"> Continue Reading